Alpha Cognition Inc. (ACOG)
| Market Cap | 198.80M +32.7% |
| Revenue (ttm) | 10.83M +269.6% |
| Net Income | -25.42M |
| EPS | -1.37 |
| Shares Out | 21.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,651 |
| Open | 8.80 |
| Previous Close | 8.67 |
| Day's Range | 8.60 - 9.21 |
| 52-Week Range | 4.50 - 10.10 |
| Beta | 2.23 |
| Analysts | Buy |
| Price Target | 16.00 (+75.25%) |
| Earnings Date | Aug 13, 2026 |
About ACOG
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impa... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACOG stock is "Buy." The 12-month stock price target is $16.0, which is an increase of 75.25% from the latest price.
News
Alpha Cognition Inc trading resumes
10:05 EDT Alpha Cognition (ACOG) Inc trading resumes
Alpha Cognition Inc trading halted, volatility trading pause
10:00 EDT Alpha Cognition (ACOG) Inc trading halted, volatility trading pause
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...
Alpha Cognition announces EPO granted patent covering benzgalantamine
Alpha Cognition (ACOG) announced that the European Patent Office, EPO, has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the…
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeut...
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for ...
Alpha Cognition initiated with an Outperform at Raymond James
Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition (ACOG) with an Outperform rating and $20 price target Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine, ...
Alpha Cognition appoints Robert Wills as chairman of the board
Alpha Cognition (ACOG) announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years…
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for ...
Alpha Cognition announces enrollment of first patient in Resolve
Alpha Cognition (ACOG) announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience ...
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovati...
Alpha Cognition reports results from Beacon real-world study of Zunevyl
Alpha Cognition (ACOG) announced the top-line results from its Beacon real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care re...
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...
Maxim starts Alpha Cognition at Buy, sees ‘significant’ market opportunity
As previously reported, Maxim analyst Naz Rahman initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $12 price target The company initiated commercialization of Zunveyl, targeting treat...
Alpha Cognition initiated with a Buy at Maxim
Maxim initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $12 price target
Alpha Cognition Slides: Corporate presentation
Alpha Cognition has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Alpha Cognition reports Q1 EPS (32c) vs (11c) last year
Reports Q1 revenue $3.534M vs $2.929M last year. “The first quarter of 2026 marked our fourth full quarter of commercial operations for ZUNVEYL, the first new oral Alzheimer’s treatment approved…
Alpha Cognition Earnings Call Transcript: Q1 2026
Q1 2026 saw 40% sequential revenue growth, strong prescriber and facility adoption, and expanded clinical and commercial initiatives. Operating loss increased due to deliberate investment, but the company remains on track for 2027 profitability and maintains a strong cash position.
Alpha Cognition Quarterly report: Q1 2026
Alpha Cognition has published its Q1 2026 quarterly earnings report on May 14, 2026.
Alpha Cognition Earnings release: Q1 2026
Alpha Cognition released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...
Alpha Cognition Proxy statement: Proxy filing
Alpha Cognition filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Alpha Cognition Proxy statement: Proxy filing
Alpha Cognition filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it wi...
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therape...